OmniAb Stock Jumps After Naming Life Sciences Veteran as New COO

Shares of OmniAb Inc. (NASDAQ:OABI) rose sharply in premarket trading on Monday after the biotechnology company announced a key executive appointment. The stock climbed 7.6% following the news that Amechi Nwachuku will join the firm in the newly-created position of Executive Vice President and Chief Operating Officer.

The New Appointment

In his new role, Nwachuku will be responsible for overseeing the strategy, operations, and commercial development of OmniAb's xPloration platform, according to the company's announcement. The xPloration platform is a single B-cell screening technology designed for high-throughput drug discovery.

OmniAb's CEO, Matt Foehr, stated that Nwachuku's experience will strengthen the executive team and help the company capitalize on market opportunities for the platform. The move is intended to support the growth of a key technology that complements OmniAb's core business of licensing antibody discovery tools.

Nwachuku's Background

Amechi Nwachuku brings over 25 years of experience from the life sciences tools sector. His previous roles include:

Ad

• Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific
• Senior Vice President, Global Commercial, SCIEX at Danaher Corporation
• Senior positions at Beckman Coulter Diagnostics, Johnson & Johnson Diabetes Care, and Bayer

Nwachuku holds a Bachelor of Science in Chemical Engineering and an MBA from the Massachusetts Institute of Technology (MIT).

Context for Investors

The positive market reaction suggests investor confidence that Nwachuku's extensive commercial and operational experience will accelerate the growth of the xPloration platform. OmniAb has indicated that this platform is a key part of its strategy to expand revenue opportunities beyond its established and strong-performing technology licensing business, which has a growing portfolio of programs that generate milestones and royalties.